{"id":252723,"date":"2025-07-10T05:59:15","date_gmt":"2025-07-10T05:59:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/252723\/"},"modified":"2025-07-10T05:59:15","modified_gmt":"2025-07-10T05:59:15","slug":"watchdog-bans-host-of-weight-loss-jab-adverts-the-latest-national-and-international-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/252723\/","title":{"rendered":"Watchdog bans host of weight-loss jab adverts | The latest National and International News"},"content":{"rendered":"\n<p>Among the banned advertisements was an Instagram post by Collins on January 6, which promoted the weight-loss service Yazen. <\/p>\n<p>In the video, Collins stated: &#8220;I&#8217;m starting this year two sizes down, thanks to Yazen&#8217;s weight loss app and medication. It&#8217;s really quick and easy to get started with Yazen, it has absolutely changed my life\u2026 I finally found something that actually I lose weight on.&#8221;<\/p>\n<p>She continued: &#8220;Yes, there&#8217;s, you know, reports and stuff. And I&#8217;m not telling anyone to go on this medication, but it is prescribed on the NHS.&#8221; <\/p>\n<p>Two complainants challenged whether the ad breached rules because it promoted prescription-only medication to the public.<\/p>\n<p>Yazen said the post was intended to share information about their &#8220;holistic, responsible approach to weight loss&#8221; rather than focus solely on medication. <\/p>\n<p>Following notification of the complaint, and in agreement with Collins, the post has been amended to remove any reference to prescription-only medications.<\/p>\n<p>Collins said she took her responsibilities under the advertising code seriously and strove to comply with them.<\/p>\n<p>Yazen said they would ensure that future posts were compliant with the advertising code.<\/p>\n<p>Other providers<\/p>\n<p>The ASA also banned an advertisement from CheqUp for prescription-only weight-loss medication that read: &#8220;No GP or pharmacy visit, just a 2 minute online consultation.&#8221; <\/p>\n<p>CheqUp told the watchdog they believed the ad followed widespread industry practice but assured it would not appear again.<\/p>\n<p>Other providers that have had ads banned include pharmacyonline.co.uk, HealthExpress.co.uk, Juniper UK, Cloud Pharmacy, Phlo Clinic and SemaPen. <\/p>\n<p>The ASA said the rulings established the advertising of named weight-loss drugs such as Wegovy, Mounjaro, Ozempic and Saxenda was banned, as was the use of various claims such as \u201cobesity treatment jab\u201d and \u201cweight loss pen\u201d.<\/p>\n<p>In April, the ASA said a search in January found around 1,800 unique paid-for weight-loss ads which were identified as potentially advertising a prescription-only medicine.<\/p>\n<p>It has published a joint Enforcement Notice with the Medicines and Healthcare products Regulatory Agency and General Pharmaceutical Council, making clear that ads for named weight-loss prescription-only medications are prohibited, including online, on social media and by influencers.<\/p>\n<p>(PA) Note: This article has been edited with the help of Artificial Intelligence.<\/p>\n","protected":false},"excerpt":{"rendered":"Among the banned advertisements was an Instagram post by Collins on January 6, which promoted the weight-loss service&hellip;\n","protected":false},"author":2,"featured_media":252724,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,12,97349,16,15],"class_list":{"0":"post-252723","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-news","11":"tag-people-shows","12":"tag-uk","13":"tag-united-kingdom"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/252723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=252723"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/252723\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/252724"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=252723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=252723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=252723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}